Kezar Life Sciences, Inc.(KZR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 46 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
KZR Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Kezar Life Sciences, Inc. (KZR), a Healthcare sector company. KZR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 46 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), Kezar Life Sciences, Inc. reports net income of $-5.8M, free cash flow of $-7.4M. Top institutional holders of KZR by reported 13-F value include BML Capital Management,, SUVRETTA CAPITAL MANAGEMENT,, TANG CAPITAL MANAGEMENT, based on the most recent SEC filings. KZR trades on the Nasdaq exchange and files with the SEC under CIK 1645666. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KZR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kezar Life Sciences, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-5.8M
Free Cash Flow
Q1 2026
$-7.4M
Get alerted when KZR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Kezar Life Sciences, Inc. including:
Top Institutional Holders of KZR
BML Capital Management, LLC
$5.3M720,787 shSUVRETTA CAPITAL MANAGEMENT, LLC
$5.3M716,759 shTANG CAPITAL MANAGEMENT LLC
$4.9M664,314 shVANGUARD CAPITAL MANAGEMENT LLC
$2.2M290,529 shRangeley Capital, LLC
$1.8M243,073 shAffinity Asset Advisors, LLC
$1.7M229,076 shRENAISSANCE TECHNOLOGIES LLC
$1.4M188,426 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$1.1M149,800 shMILLENNIUM MANAGEMENT LLC
$1.1M142,050 shPeapod Lane Capital LLC
$924.5K126,692 sh
| Fund | Value | Shares |
|---|---|---|
| BML Capital Management, LLC | $5.3M | 720,787 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | $5.3M | 716,759 |
| TANG CAPITAL MANAGEMENT LLC | $4.9M | 664,314 |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.2M | 290,529 |
| Rangeley Capital, LLC | $1.8M | 243,073 |
| Affinity Asset Advisors, LLC | $1.7M | 229,076 |
| RENAISSANCE TECHNOLOGIES LLC | $1.4M | 188,426 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.1M | 149,800 |
| MILLENNIUM MANAGEMENT LLC | $1.1M | 142,050 |
| Peapod Lane Capital LLC | $924.5K | 126,692 |
More Healthcare Companies
View all Healthcare →Put KZR on your watchlist
Track score changes the day Kezar Life Sciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KZR a good stock to buy?
13F Pro's AI-powered analysis of Kezar Life Sciences, Inc. (KZR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KZR are available on the KZR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own KZR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KZR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Kezar Life Sciences, Inc.'s investment landscape.